FERNAND LABRIE
No ORCID on file
· 14 papers in corpus
· active 1990-2007
Study types
- article 1
- other 1
Condition tags
- endometriosis 2
Top journals
Frequent coauthors
- Labrie F 2
- Morissette J 2
- Belanger A 1
- Calvo E 1
- Cusan L 1
- Céline Martel 1
- Durocher F 1
- Dupont A 1
- Dupont P 1
- Belleau P 1
other
2007
17beta-Estradiol (E2) is well known to be associated with uterine cancer, endometriosis, and leiomyomas. Although insulin-like growth factor I (IGF-I) has been identified as a mediator of the uterotrophic effect of E2 in several studies, th…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
2006
Androst-5-ene-3 beta ,17 beta diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido,…
article
1990
The effect of medical oophorectomy induced by treatment with the luteinizing hormone-releasing hormone (LH-RH) agonist [D-Trp6,des-Gly-NH2(10)]LH-RH ethylamide was studied in 34 patients with laparoscopically proven endometriosis. Tamoxifen…